Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world IL-17A biologics with or without dupilumab for Netherton syndrome
ChiCTR2200065139Phase 4Recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab, ixekizumab and dupilumab in Netherton syndrome (NS), sponsored by Southern Medical University Dermatology Hospital. Primary endpoints: Investigator’s Global Assessment (IGA) of skin, Erythema and Scaling Area and Severity Index (EASI) and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on ChiCTR2200065139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065139.